Kidney, pancreas, and pancreatic islet transplantation

British Columbia Medical Journal

Volumn 52, Issue 4, 2010, Pages 189-196

  Landsberg, David N ^a,b   Shapiro, R Jean ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951985410     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729.
2. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-2575.
3. Vincenti F, Schena FP, Paraskevas S, et al. drawal or standard steroid therapy in kidney transplant recipients. Am J Trans-plant 2008;8:307-316.
4. Gebel H, Bray R, Nickerson P. Pre-trans-plant assessment of donor-reactive, HLA-specific antibodies in renal trans-plantation: Contraindication vs. risk. Am J Transplant 2003;3:1488-1500.
5. Bray R, Nolen J, Larsen C, et al. Trans-planting the highly sensitized patient: The emory algorithm. Am J Transplant 2006;6:2307-2315.
6. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intra-venous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-2113.
7. Weir M. Preemptive kidney transplanta-tion: Why not? Am J Transplant 2003;3: 1336-1340.
8. Chkhotua AB, Klein T, Shabtai E, et al. Kidney transplantation from living-unrelated donors: Comparison of outcome with living-related and cadaveric trans-plants under current immunosuppressive protocols. Urology 2003;62:1002-1006.
9. Henderson AJZ, Landolt MA, McDonald MF, et al. The living anonymous kidney donor: Lunatic or saint? Am J Transplant 2003;3:203-213.
10. Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006;1:532-538.
11. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005;294:2726-2733.
12. Wolfe R, McCullough K, Schaubel D, et al. Calculating life years from transplant (LYFT): Methods for kidney and kidney-pancreas candidates. Am J Transplant 2008;8:987-1011.
13. McCullough KP, Keith DS, Meyer KH, et al. Kidney and pancreas transplantation in the United States, 1998-2007: Access for patients with diabetes and end-stage renal disease. Am J Transplant 2009;9: 894-906.
14. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001;71:82-90.
15. White SA, Shaw JA, Sutherland DE. Pan-creas transplantation. Lancet 2009;373 (9677):1808-1817.
16. Kaplan B, West-Thielke PM, Herren H, et al. Reported isolated pancreas rejection is associated with poor kidney outcomes in recipients of a simultaneous pancreas kidney transplant. Transplantation 2008; 86:1229-1233.
17. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pan-creas allograft rejection: Working pro-posal by a multi-disciplinary international consensus panel. Am J Transplant 2008; 8:1237-1249.
18. Gruessner RW, Sutherland DE, Gruess-ner AC. Mortality assessment for pan-creas transplants. Am J Transplant 2004; 4:2018-2026.
19. Shapiro AMJ, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glu-cocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-238.
20. Robertson RP, Davis C, Larsen J, et al. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006;29:935.
21. Bromberg JS, Kaplan B, Halloran PF, et al. The islet transplant experiment: Time for a reassessment. Am J Transplant 2007; 7:2217-2218.
22. Merani S, Toso C, Emamaullee J, et al. Optimal implantation site for pancreatic islet transplantation. Br J Surgery 2008; 95:1449-1461.
23. Warnock GL, Thompson DM, Meloche RM, et al. A multiyear analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008;86:1762-1766.
24. Fiorina P, Shapiro AM, Ricordi C, et al. The clinical impact of islet transplantation. Am J Transplant 2008;8:1990-1997.
25. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: Safety, efficacy, and metabolic effects. Transplantation 2008;86:36-45.
26. Fung M, Thompson DM, Shapiro RJ, et al. Effect of glucagon-like peptide-1 (7- 37) on beta-cell function after islet trans-plantation in type 1 diabetes. Diabetes Res Clin Pract 2006;74:189-193.
27. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007; 7:2311-2317.
28. Alejandro R, Barton FB, Hering BJ, et al. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation 2008;86:1783-1788.